SAGE Therapeutics (NASDAQ:SAGE) Announces Quarterly Earnings Results

Share on StockTwits

SAGE Therapeutics (NASDAQ:SAGE) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($3.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.41) by ($0.07), Fidelity Earnings reports. SAGE Therapeutics had a negative return on equity of 59.37% and a negative net margin of 12,931.34%. The firm had revenue of $3.57 million for the quarter, compared to analyst estimates of $2.52 million. During the same period in the prior year, the company posted ($2.63) EPS. The firm’s quarterly revenue was up 35600.0% compared to the same quarter last year.

Shares of SAGE traded up $3.43 during trading hours on Friday, reaching $144.22. The stock had a trading volume of 1,893 shares, compared to its average volume of 366,793. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.03. SAGE Therapeutics has a 52 week low of $79.88 and a 52 week high of $193.56. The firm has a 50-day moving average of $141.94 and a 200 day moving average of $163.62. The company has a market cap of $7.31 billion, a P/E ratio of -17.75 and a beta of 2.49.

Several research analysts have issued reports on SAGE shares. Canaccord Genuity reduced their price objective on SAGE Therapeutics from $220.00 to $218.00 and set a “buy” rating on the stock in a report on Wednesday. JPMorgan Chase & Co. restated a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. ValuEngine cut shares of SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday. William Blair restated a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. Finally, Oppenheimer lowered their price objective on shares of SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the stock. SAGE Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $201.00.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Recommended Story: What is Net Asset Value (NAV)?

Earnings History for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

FNB Protocol Trading Down 34.5% This Week
FNB Protocol Trading Down 34.5% This Week
Achain  Price Hits $0.0062 on Exchanges
Achain Price Hits $0.0062 on Exchanges
Odyssey Trading Up 14.1% This Week
Odyssey Trading Up 14.1% This Week
DURECT  Upgraded by BidaskClub to Buy
DURECT Upgraded by BidaskClub to Buy
Telefonaktiebolaget LM Ericsson  Upgraded at ValuEngine
Telefonaktiebolaget LM Ericsson Upgraded at ValuEngine
Expedia Group  PT Lowered to $125.00
Expedia Group PT Lowered to $125.00


© 2006-2019 Ticker Report